Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02574663 · ClinicalTrials.gov registry record · Phase 1
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02574663 is a Phase 1 study that has completed, run by TG Therapeutics. The registered enrollment target is 66 participants.
The verdict
NCT02574663, a Phase 1 study, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.
Interventions
- DRUG TGR-1202
- DRUG nab-paclitaxel + gemcitabine
- DRUG Oxaliplatin + Folinic acid + Fluorouracil
- DRUG Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-09-11 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02574663
The ClinicalTrials.gov registry entry for NCT02574663 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which TGR-1202 is the first listed.
NCT02574663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02574663 about?
NCT02574663 is a clinical study titled "TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors". This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.
What is the current status of trial NCT02574663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2015-09-11. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02574663?
The interventions under investigation include: TGR-1202 (DRUG), nab-paclitaxel + gemcitabine (DRUG), Oxaliplatin + Folinic acid + Fluorouracil (DRUG), Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT02574663?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.